Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an announcement.
Prescient Therapeutics Limited has successfully raised $6.8 million through its Share Purchase Plan to advance the clinical development of its cancer treatment, PTX-100, particularly its Phase 2 clinical trials. The company has also initiated a follow-on placement for sophisticated and professional investors at a discounted share price to further support its commercialization objectives. This funding is pivotal for Prescient as it aims to bring PTX-100 closer to regulatory approval, addressing significant unmet medical needs in cancer treatment.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches to cancer, including targeted and cellular therapies. Their primary product, PTX-100, is a first-in-class compound that inhibits the cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), disrupting oncogenic Ras pathways and inducing apoptosis in cancer cells. PTX-100 has shown promising results in clinical trials and has received Orphan Drug and Fast Track Designations from the US FDA.
Average Trading Volume: 1,096,492
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$36.24M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.